Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Webcast of the ImmunoGen, Inc. Analyst & Investor Event on September 18, 2015
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of
View HTML
Toggle Summary ImmunoGen, Inc. Announces Morgan Stanley Global Healthcare Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Morgan Stanley Global Healthcare Conference .
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that investors, journalists and the general public are invited to listen to a live webcast of
View HTML
Toggle Summary ImmunoGen, Inc. Announces Canaccord Genuity Growth Conference Webcast
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the Company will participate in the Canaccord Genuity 35 th Annual Growth Conference.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2015 Financial Results
− Company Provides Corporate Update and Fiscal Year 2016 Financial Guidance − − Conference Call Today at 8:00 am ET − ImmunoGen's wholly owned mirvetuximab soravtansine demonstrates notable single-agent activity in early clinical testing for platinum-resistant ovarian cancer; Company plans to
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Fourth Quarter and Fiscal Year 2015 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML